Clinical Trial

NSAID Use for Treating Dysmenorrhea and Preventing Chronic Pelvic Pain (NSAID HEAL)

Study acronym: NSAIDHEAL
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if NSAIDs (i.e. naproxen sodium) can treat menstrual pain and prevent the development of chronic pelvic pain in menstruating adults with painful periods. The main questions it aims to answer are: * Can non-menstrual pelvic pain reduction be predicted by menstrual pain response to NSAIDs? * Will participants with the largest reductions in multi-site sensitivity following NSAID therapy have the largest reductions in non-menstrual pelvic pain? Researchers will compare naproxen sodium to a placebo (a look-alike substance that contains no drug) to see if naproxen sodium works to treat painful periods. Participants will: * Take naproxen sodium or placebo during several days of their menstrual period every month for 1 year. * Complete computer questionnaires and tests from home every 3 months. * Complete at-home urine tests to measure hormones every few days for 1-year. * Use a pin-prick to collect a small spot of blood, and use a pad or tampon to collect a sample of menstrual blood, and bring it to the research site twice over a 1-year period. * Come to the research site twice over a 1-year period to complete sensory assessments and undergo a blood draw. The major goal of the study is to develop a multivariable statistical model (see https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-24-021.html ) describing the factors that effectiveness of pain medication and risk for chronic pain
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-05.
Trial Details
NCT Number NCT06861920
Lead Sponsor Endeavor Health
Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Chicago, University of Oklahoma
Conditions Dysmenorrhea, Chronic Pelvic Pain, Pelvic Pain
Enrollment 600 participants
Start Date 2025-04-07
Primary Completion 2030-04 (estimated)
Study Completion 2030-07 (estimated)
Updated on ClinicalTrials.gov 2025-08-07